Zai Ding Pharmaceuticals (09688.HK) total revenue in the third quarter increased by 14% year-on-year to reach 116.1 million US dollars.

Financial news from Wisdom Financial APP, Reistone Medicine (09688.HK) announced its third quarter performance in 2025, with total revenue increasing by 14% year-on-year to $116.1 million; operating loss was $48.8 million, narrowing by 28% year-on-year, and adjusted operating loss narrowed by 42% to $28 million; adjusted full-year total revenue guidance for 2025 is at least $460 million.